Home > Inhibitors & Agonists > Tyrosine Kinase > VEGFR
Cat. No. Product name CAS No.
DC4231 Linifanib (ABT-869)

ABT-869 is an ATP-competitive, multi-targeted RTK inhibitor that is completely effective against all members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families.

796967-16-3
DC11512 Acrizanib

Acrizanib(LHA510) is a potent and selective angiogenesis inhibitor and VEGFR‑2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

1229453-99-9
DC8072 Altiratinib(DCC-2701)

Altiratinib is a MET/TIE2/VEGFR2/TRK (A,B,C) kinase inhibitor in Phase 1 clinical development for the treatment of invasive solid tumors including glioblastoma.

1345847-93-9
DC4101 Apatinib Mesylate

Apatinib (YN968D1) is an orally bioavailable, selective VEGFR2 inhibitor with IC50 of 1 nM.

1218779-75-9
DCAPI1524 Axitinib

Axitinib is a non-selective receptor kinase inhibitor of Flt and Flk proteins. This compound also inhibits VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β and c-KIT with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. Axitinib is studied as an ant

319460-85-0
DC9956 BFH772

BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM.

890128-81-1
DC2019 Brivanib (bms-540215)

Brivanib is an ATP-competitive inhibitor against human VEGFR2 and FGFR with IC50 of 25 nM and 148 nM, respectively.

649735-46-6
DC9266 Cabozantinib S-malate

Cabozantinib S-malate (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM, respectively.

1140909-48-3
DC3170 Cediranib

Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM.

288383-20-0
DC4132 CP-547632

CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively).

252003-65-9
DC3141 Dovitinib (TKI258) Lactate

Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively.

915769-50-5
DC7128 Lucitanib(E3810)

E-3810 is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity.

1058137-23-7
DC8488 LENVATINIB MESYLATE

E7080 (Lenvatinib) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β.

857890-39-2
DC7116 E7080 (Lenvatinib)

E7080 (Lenvatinib; Vargatef) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β.

417716-92-8
DC7902 Fruquintinib (HMPL-013)

Fruquintinib (HMPL-013) is a novel small molecule compound that selectively inhibits vascular endothelial growth factor receptors (VEGFRs).

1194506-26-7
DC10123 JI-101

JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4).

900573-88-8
DC10595 JK-P3

JK-P3 is a VEGFR-2 inhibitor.

942655-44-9
DC8521 JNJ-38158471

JNJ-38158471(KDR) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50=40nM. It also inhibits closely related tyrosine kinases, Ret (180nM) and Kit (500nM). It has no significant activity (>1 microM) against VEGFR-1 and VEGF

951151-97-6
DC7440 KI8751

Ki8751 is a potent and selective inhibitor of VEGFR2 with IC50 of 0.9 nM, >40-fold selective for VEGFR2 than c-Kit, PDGFRα and FGFR-2, little activity to EGFR, HGFR and InsR.

228559-41-9
DC10454 KRN633

KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells.

286370-15-8
DC11285 MAZ51

MAZ51 is an indolinone that selectively antagonizes the activation of VEGFR3 by VEGFC (IC50 = 1 µM) without blocking VEGFC-mediated stimulation of VEGFR2.

163655-37-6
DC7462 MGCD-265

MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2.

875337-44-3
Page 1 / Total 3 FirstPrevNextLastGoto